Targeted integration cell and preparation method thereof, and method for producing target gene expression product
Through targeted integration of cell technology, specific nucleic acid fragments and recombinases are used for site-based integration, the problems of instable gene expression and low yield in traditional cell line construction are solved, and efficient and controllable cell line construction is achieved, reducing costs and time.
Patent Information
- Application Number
- CN202210707236.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-06-21
AI Technical Summary
Random integration of traditional cell line construction methods leads to unstable gene expression, low yield and complex process, time-consuming and high cost, making it difficult to predict expression stability.
Using targeted integrated cell technology, exogenous nucleotide sequences are integrated through the nucleic acid fragment shown in SEQ ID No.1, recombinant enzymes such as Bxb1, ΦC31, Cre or FLP for site-directed integration, and combined with selectable marker genes and promoters to construct Recombinant vectors to achieve stable and high-yield expression of target genes.
It improves the controllability and repetition of the integration process, simplifies screening and process development steps, reduces cost and time, improves the stability and yield of cell lines, and reduces uncertainty.
Smart Images

Figure CN117305334B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to targeted integrated cells and preparation methods thereof, and methods for producing target gene expression products. Background Art
[0002] With the continuous development of the biopharmaceutical industry, the requirements for product expression level and expression stability are gradually increasing, and cell line construction is a key factor in determining product expression yield and expression stability.
[0003] Traditional cell line construction strategies mainly rely on random integration of nucleotide sequences encoding target polypeptides. This approach has several shortcomings, including:
[0004] From the construction process, after the target gene is transfected into CHO cells, after a period of pressure screening, the target gene will gradually integrate into the host cell genome. Due to the low integration frequency and strong randomness, the resulting screening population (i.e., cell pool) presents complex diversity, which may lead to a variety of gene expression and cell growth phenotypes, known as "position effect variation". In addition, a large number of monoclonal blind selections and amplifications are required to finally determine high-yield and stable cell lines. This method requires a lot of screening work for each cell pool, and subsequent process development and culture medium optimization for each cell line are required, which consumes a lot of repetitive labor, resulting in waste of resources and high costs.
[0005] In terms of the quality of cell line preparation, the expression stability of cell lines obtained based on traditional random integration strategies is difficult to predict during the culture process (especially in the late culture period). In addition, the information of random integration sites is unclear, and the site effect of exogenous target gene integration will also lead to a significant decrease in the expression level of the target gene. Although the use of high-rigor selection systems such as the GS (glutamine synthetase) gene expression system to enrich high-yield cell lines can produce gene amplification and increase gene copy number, it sometimes leads to unstable cell growth and / or product expression.
[0006] Using the targeted integration cell sites that are stable and highly expressed target genes to integrate the target genes into the targeted integration cells can improve the controllability and repeatability of the integration process, facilitate the stable and high-yield expression of the target genes, and simplify the subsequent screening and process development steps. Therefore, it is necessary to develop a targeted integration cell for site-specific integration of exogenous nucleotide sequences. Summary of the invention
[0007] Based on this, the purpose of the present invention includes providing a targeted integration cell, which comprises a nucleic acid fragment shown in SEQ ID No. 1 and an exogenous nucleotide sequence is integrated into the nucleic acid fragment.
[0008] The purpose of the present invention can be achieved by the following technical solutions:
[0009] In a first aspect of the present invention, a nucleic acid is provided, wherein the nucleic acid comprises a nucleic acid fragment shown in SEQ ID No. 1, wherein an exogenous nucleic acid fragment is integrated into the nucleic acid fragment.
[0010] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 100th to 3000th base interval of the nucleic acid fragment.
[0011] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 150th to 2820th base interval of the nucleic acid fragment.
[0012] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 324th to 2688th base interval of the nucleic acid fragment.
[0013] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 480th to 2460th base interval of the nucleic acid fragment.
[0014] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 700th to 2200th base interval of the nucleic acid fragment.
[0015] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 976th to 1900th base interval of the nucleic acid fragment.
[0016] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 1260th-1879th base interval of the nucleic acid fragment.
[0017] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 1561st-1800th base interval of the nucleic acid fragment.
[0018] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 1678th-1744th base interval of the nucleic acid fragment.
[0019] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 1701-1720 base interval of the nucleic acid fragment.
[0020] In some embodiments of the present invention, the exogenous nucleic acid fragment comprises: a first recombination recognition sequence and a second recombination recognition sequence recognized by a recombinase, a selection marker gene and a target gene located between the first recombination recognition sequence and the second recombination recognition sequence, and a promoter that regulates the expression of the selection marker gene and the target gene.
[0021] In some embodiments of the present invention, the recombinase is Bxb1 integrase, ΦC31 integrase, Cre recombinase or FLP recombinase.
[0022] In some embodiments of the present invention, the first recombination recognition sequence and the second recombination recognition sequence are independently selected from one or more of the following sequences: LoxP sequence, LoxPL3 sequence, LoxP 2L sequence, LoxFas sequence, Lox511 sequence, Lox2272 sequence, Lox2372 sequence, Lox5171 sequence, Loxm2 sequence, Lox71 sequence, Lox66 sequence, FRT sequence, Bxb1 attP sequence, Bxb1 attB sequence, attP sequence and attB sequence.
[0023] In some embodiments of the present invention, the selection marker gene is selected from one or more of a neomycin resistance gene, a thymidine kinase gene, a hygromycin phosphotransferase gene, a dihydrofolate reductase gene, a thymidine kinase gene, a glutamine synthetase gene, an asparagine synthetase gene, a tryptophan synthetase gene, a histidinol dehydrogenase gene, an aminoglycoside phosphotransferase gene, a tryptophan synthetase gene and a fluorescent protein gene.
[0024] In some embodiments of the present invention, the promoter is a CMV promoter, an SV40 promoter, an RSV promoter, a β-globin promoter, a UBC promoter, an EF1a promoter, an ubiquitin promoter, a β-actin promoter, a PGK1 promoter, a Rosa26 promoter, a HSP70 promoter, a GAPDH promoter, an Eif4A1 promoter, an Egr1 promoter, a FerH promoter, a SM22α promoter or an Endothelin-1 promoter.
[0025] In some embodiments of the present invention, the target gene encodes one or more of an antibody, a recombinant protein, a polypeptide, an enzyme, a hormone, a growth factor and a receptor.
[0026] In a second aspect of the present invention, a recombinant vector is provided, comprising:
[0027] a. a 5' homology arm homologous to the sequence fragment present in the nucleic acid fragment shown in SEQ ID No.1,
[0028] b. Target gene,
[0029] c. A 3' homology arm that is homologous to the sequence fragment present in the nucleic acid fragment shown in SEQ ID No.1.
[0030] In some embodiments of the present invention, the recombinant expression vector is a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a herpes virus vector, a poxvirus vector, a baculovirus vector, a papillomavirus vector, a papillomas virus vector, an integrative phage vector, a non-viral vector, a transposon and / or a transposase, an integrase substrate or a plasmid.
[0031] In the third aspect of the present invention, a targeted integrated cell is provided, wherein the targeted integrated cell comprises the nucleic acid described in the first aspect.
[0032] In some embodiments of the present invention, the targeted integration cell is a eukaryotic cell.
[0033] In some embodiments of the invention, the eukaryotic cell is a mammalian cell.
[0034] In some embodiments of the present invention, the targeted integration cells include Chinese hamster ovary CHO cells and human embryonic kidney HEK293 cells.
[0035] In a fourth aspect of the present invention, a method for preparing the targeted integrated cell according to the third aspect is provided, the preparation method comprising the following steps:
[0036] The nucleic acid described in the first aspect is introduced into a cell, or a cell containing the nucleic acid fragment shown in SEQ ID No. 1 is provided and the exogenous nucleic acid fragment is integrated into the nucleic acid fragment to prepare a targeted integrated cell.
[0037] In a fifth aspect of the present invention, a method for producing a target gene expression product is provided, the method comprising the following steps: culturing the targeted integration cell described in the third aspect, and collecting the target gene expression product.
[0038] Compared with the conventional technology, the present invention has the following beneficial effects:
[0039] After a large number of preliminary screenings, the present invention found that corresponding to the nucleic acid fragment shown in SEQ ID No. 1 or a homologous fragment that maintains at least 90% identity therewith, an exogenous nucleotide sequence (including a target gene, etc.) is integrated into the nucleic acid fragment or its homologous fragment, and the corresponding targeted integrated cells are stable and high-yielding.
[0040] Furthermore, the targeted integrated cells of the present invention have low requirements on subsequent culture processes (eg, culture conditions, culture medium formulations) due to their stability and high yield characteristics.
[0041] At the same time, the present invention provides targeted integration cells, and the insertion site of the exogenous nucleotide sequence is determined. Therefore, compared with the traditional random integration cell construction method, the construction process required for the targeted integration cells of the present invention is simple, time-consuming, efficient, cost-effective, and has reduced uncertainty, good repeatability, and strong controllability. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] In order to more clearly illustrate the technical solutions in the embodiments of the present invention and to more completely understand the present invention and its beneficial effects, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention, and those skilled in the art can obtain other drawings based on these drawings without creative work.
[0043] Figure 1 This is an operation flow chart of Example 1;
[0044] Figure 2 This is a schematic diagram of RMCE for site screening in Example 1;
[0045] Figure 3 This is the recombinant plasmid map used for site screening in Example 1;
[0046] Figure 4 This is the result diagram of GBB-01 fluorescent mother cell growth stability;
[0047] Figure 5 This is a schematic diagram of RMCE for target gene transfection in Example 1;
[0048] Figure 6 This is the recombinant plasmid map used for target gene transfection in Example 1;
[0049] Figure 7 This is a graph showing the evaluation results of the target gene expression level of the targeted integrated cells prepared in Example 1;
[0050] Figure 8 This is a graph showing the stability evaluation results of the targeted integrated cell expression prepared in Example 1;
[0051] Fig. 9 This is a graph showing the stability evaluation results of the targeted integrated cell specific yield prepared in Example 1;
[0052] Fig.10 A comparison chart of the sugar profile of the targeted integrated cell product and the random integrated control cell product prepared in Example 1;
[0053] Fig.11 A comparison diagram of the charge heterogeneity of the targeted integration cells and random integration control cells prepared in Example 1;
[0054] Fig.12 This is a verification diagram of the targeted integration cell integration site prepared in Example 1. DETAILED DESCRIPTION
[0055] The present invention will be further described in detail below in conjunction with the accompanying drawings, embodiments and examples. It should be understood that these embodiments and examples are only used to illustrate the present invention and are not used to limit the scope of the present invention. The purpose of providing these embodiments and examples is to make the understanding of the disclosure of the present invention more thorough and comprehensive. It should also be understood that the present invention can be implemented in many different forms and is not limited to the embodiments and examples described herein. Those skilled in the art can make various changes or modifications without violating the connotation of the present invention, and the equivalent form obtained also falls within the protection scope of the present invention. In addition, in the following description, a large number of specific details are given in order to provide a more comprehensive understanding of the present invention. It should be understood that the present invention can be implemented without one or more of these details.
[0056] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing implementation modes and embodiments and are not intended to limit the present invention.
[0057] the term
[0058] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:
[0059] In the present invention, “further”, “furthermore”, “particularly”, etc. are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present invention.
[0060] In the present invention, "optionally", "optional", and "optional" mean optional, that is, any one of the two parallel solutions of "yes" or "no". If multiple "options" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent.
[0061] In the present invention, in the "first aspect", "second aspect", "third aspect", "fourth aspect", etc., the terms "first", "second", "third", "fourth", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.
[0062] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0063] In the present invention, when it comes to numerical intervals (i.e., numerical ranges), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval, and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, and each numerical value between the two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to the integers within the numerical interval, it includes the two endpoint integers of the numerical range, and each integer between the two endpoints. In this article, it is equivalent to directly listing each integer, such as t is an integer selected from 1-10, indicating that t is any integer selected from the integer group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all sub-ranges included therein.
[0064] All documents mentioned in the present invention are cited as references in the present invention, just as each document is cited as a reference separately. Unless they conflict with the invention purpose and / or technical solution of the present invention, the cited documents involved in the present invention are cited with all contents and all purposes. When the present invention involves cited documents, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When the present invention involves cited documents, the examples and preferred embodiments of the cited relevant technical features can also be incorporated into the present invention as references, but are limited to the ability to implement the present invention. It should be understood that when the cited content conflicts with the description in the present invention, the present invention shall prevail or be modified adaptively according to the description of the present invention.
[0065] In the present invention, "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, according to the practice in the art, "about" can mean within 3 or more than 3 standard deviations. Alternatively, "about" can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and even more preferably up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude of a value, preferably within 5-fold, and more preferably within 2-fold.
[0066] In the present invention, a "selection marker gene" may be a gene that allows targeted integration cells carrying the gene to be specifically selected for or against the gene in the presence of a corresponding selection agent. For example, but not limiting, a selection marker may allow targeted integration cells transformed with a selection marker gene to be positively selected in the presence of the gene; non-transformed targeted integration cells will not be able to grow or survive under selection conditions. The selection marker may be positive, negative or bifunctional. A positive selection marker may allow cells carrying the marker to be selected, while a negative selection marker may allow cells carrying the marker to be selectively eliminated. The selection marker may confer resistance to a drug or compensate for metabolic or catabolism defects in targeted integration cells.
[0067] In the present invention, "antibody" is used in the broadest sense and includes a variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), half antibodies and antibody fragments, as long as the fragment exhibits the desired antigen-binding activity. As used herein, the term "antibody fragment" refers to a molecule that contains a portion of an intact antibody that binds to the antigen bound by the intact antibody, in addition to the intact antibody. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed by antibody fragments. For a review of certain antibody fragments, see Holliger and Hudson, Nature Biotechnology 23: 1126-1136 (2005).
[0068] In the present invention, the term "targeted integration cell" refers to a cell into which an exogenous nucleic acid has been introduced, including the progeny of such cells. Targeted integration cells include "transformants" and "transformed cells", which include primary transformed cells and progeny derived therefrom, regardless of the number of passages. The nucleic acid content of the progeny may not be exactly the same as that of the parental cell, but may contain mutations. Mutant progeny having the same function or biological activity as that screened or selected for in the initial transformed cell are included herein.
[0069] In the present invention, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures and vectors that are incorporated into the genome of cells into which they have been introduced for targeted integration. In certain embodiments, the vector directs the expression of a nucleic acid to which it is operably linked. Such vectors are referred to herein as "expression vectors."
[0070] In the present invention, the term "homologous fragment" refers to a sequence fragment that has a significant sequence similarity as determined by sequence alignment. For example, two sequence fragments can be about 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 99.9% homologous. Alignment is performed by algorithms and computer programs (including but not limited to BLAST, FASTA and HMME), which compare sequence fragments and calculate the statistical significance of the match based on factors such as sequence length, sequence identity and similarity, and the presence and length of sequence mismatches and gaps; for example, it can be the ratio of the length of similar sequence fragments to the length of the aligned region. Homologous sequence fragments can refer to both DNA and protein sequences.
[0071] The currently disclosed subject matter provides a targeted integration cell suitable for an exogenous nucleotide sequence. In certain embodiments, the targeted integration cell comprises an exogenous nucleotide sequence integrated at an integration site on the genome of the host cell. An "integration site" comprises a nucleic acid sequence within the genome of the targeted integration cell, into which an exogenous nucleotide sequence is inserted. In certain embodiments, the integration site is between two adjacent nucleotides on the genome of the targeted integration cell. In certain embodiments, the integration site comprises a nucleotide extension, and an exogenous nucleotide sequence can be inserted between any of the nucleotides.
[0072] A first aspect of the present invention
[0073] The present invention provides a nucleic acid, which comprises a nucleic acid fragment shown in SEQ ID No. 1, wherein an exogenous nucleic acid fragment is integrated into the nucleic acid fragment.
[0074] SEQ ID No.1:
[0075]
[0076] In some embodiments of the present invention, the sequence fragment into which the exogenous nucleic acid fragment is integrated maintains no less than 90% identity with the nucleic acid fragment shown in SEQ ID No. 1, for example, 90%, 90.5%, 91%, 91.5%, 92%, 92.5%, 93%, 93.5%, 94%, 94.5%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% identity.
[0077] In some embodiments of the present invention, the integration site of the exogenous nucleic acid fragment can be the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th, ... 1679, 1680, 1681, 1682, 1683, 1684, 1685, 1686, 1687, 1688, 1689, 1690, 1691, 1692, 1693, 1694, 1695, 1696, 1697, 1698, 1699, 1700, 1701, 1702, 1703, 1704, 1705, 1706, 1707, 1708, , 1709, 1710, 1711, 1712, 1713, 1714, 1715, 1716, 1717, 1718, 1719, 1720, 1721, 1722, 1723, 1724, 1725, 1726, 1727, 1728, 1729, 1730, 1731, 1732, 1733, 1734, 1735, 1736, 1737, 1738, 1739, 1740, 1741, 1742, 1743, 1744...3145, 3146, 3147, 3148, 3149, 3150 bases.
[0078] Optionally, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 100th to 3000th base interval of the nucleic acid fragment.
[0079] Optionally, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 150th to 2820th base interval of the nucleic acid fragment.
[0080] Optionally, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 324th-2688th base interval of the nucleic acid fragment.
[0081] Optionally, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 480th-2460th base interval of the nucleic acid fragment.
[0082] Optionally, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 700th to 2200th base interval of the nucleic acid fragment.
[0083] Optionally, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 976th-1900th base interval of the nucleic acid fragment.
[0084] Optionally, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 1260th-1879th base interval of the nucleic acid fragment.
[0085] Optionally, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 1561st-1800th base interval of the nucleic acid fragment.
[0086] Optionally, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 1678th-1744th base interval of the nucleic acid fragment.
[0087] Optionally, the integration site of the exogenous nucleic acid fragment corresponds to any site within the 1701-1720 base interval of the nucleic acid fragment.
[0088] Preferably, the integration site of the exogenous nucleic acid fragment corresponds to between the 1711th and 1712th bases of the nucleic acid fragment.
[0089] In some embodiments of the present invention, the exogenous nucleic acid fragment comprises: a first recombination recognition sequence and a second recombination recognition sequence recognized by a recombinase, a selection marker gene and a target gene located between the first recombination recognition sequence and the second recombination recognition sequence, and a promoter that regulates the expression of the selection marker gene and the target gene.
[0090] In some embodiments of the present invention, the recombinase is Bxb1 integrase, ΦC31 integrase, Cre recombinase or FLP recombinase.
[0091] In some embodiments of the present invention, the first recombination recognition sequence and the second recombination recognition sequence are independently selected from one or more of the following sequences: the recombination recognition sequence is a LoxP sequence, a LoxPL3 sequence, a LoxP2L sequence, a LoxFas sequence, a Lox511 sequence, a Lox2272 sequence, a Lox2372 sequence, a Lox5171 sequence, a Loxm2 sequence, a Lox71 sequence, a Lox66 sequence, a FRT sequence, a Bxb1 attP sequence, a Bxb1 attB sequence, an attP sequence and an attB sequence.
[0092] In some embodiments of the present invention, the selection marker gene is selected from one or more of a neomycin resistance gene, a thymidine kinase gene, a hygromycin phosphotransferase gene, a dihydrofolate reductase gene, a thymidine kinase gene, a glutamine synthetase gene, an asparagine synthetase gene, a tryptophan synthetase gene, a histidinol dehydrogenase gene, an aminoglycoside phosphotransferase gene, a tryptophan synthetase gene and a fluorescent protein gene.
[0093] In some embodiments of the present invention, the promoter is a CMV promoter, an SV40 promoter, an RSV promoter, a β-globin promoter, a UBC promoter, an EF1a promoter, an ubiquitin promoter, a β-actin promoter, a PGK1 promoter, a Rosa26 promoter, a HSP70 promoter, a GAPDH promoter, an Eif4A1 promoter, an Egr1 promoter, a FerH promoter, a SM22α promoter or an Endothelin-1 promoter.
[0094] In some embodiments of the present invention, the target gene encodes one or more of an antibody, a recombinant protein, a polypeptide, an enzyme, a hormone, a growth factor and a receptor.
[0095] Second aspect of the present invention
[0096] The present invention provides a recombinant vector, comprising:
[0097] a. a 5' homology arm homologous to a sequence fragment present in a nucleic acid fragment shown in SEQ ID No.1 or a homologous fragment having at least 90% identity with the nucleic acid fragment,
[0098] b. Target gene,
[0099] c. A 3' homology arm homologous to the nucleic acid fragment shown in SEQ ID No. 1 or a sequence fragment present in a homologous fragment that maintains at least 90% identity with the nucleic acid fragment.
[0100] In some embodiments of the present invention, the recombinant expression vector is a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a herpes virus vector, a poxvirus vector, a baculovirus vector, a papillomavirus vector, a papillomas virus vector, an integrative phage vector, a non-viral vector, a transposon and / or a transposase, an integrase substrate or a plasmid.
[0101] The third aspect of the present invention
[0102] The present invention provides a targeted integrated cell, wherein the targeted integrated cell comprises the nucleic acid described in the first aspect.
[0103] In some embodiments of the present invention, the targeted integration cell is a eukaryotic cell.
[0104] In some embodiments of the invention, the eukaryotic cell is a mammalian cell.
[0105] In some embodiments of the present invention, the mammalian cells include Chinese hamster ovary CHO cells and human embryonic kidney HEK293 cells.
[0106] In some embodiments of the present invention, the CHO cell includes a CHO host cell, a CHO K1 host cell, a CHO K1SV host cell, a DG44 host cell, a DUKXB-11 host cell, a CHOK1S host cell or a CHO K1M host cell.
[0107] A fourth aspect of the present invention
[0108] The present invention provides a method for preparing the targeted integrated cell according to the third aspect, the method comprising the following steps:
[0109] The nucleic acid described in the first aspect is introduced into a cell, or a cell comprising a nucleic acid fragment shown in SEQ ID No.1 or a homologous fragment that maintains at least 90% identity with the nucleic acid fragment is provided and the exogenous nucleic acid fragment is integrated into the nucleic acid fragment shown in SEQ ID No.1 or a homologous fragment that maintains at least 90% identity with the nucleic acid fragment, to prepare a targeted integrated cell.
[0110] In some embodiments of the present invention, the integration method includes but is not limited to site-specific recombination technology derived from homologous recombination technology, which relies on integrase targeting specific recognition sites to achieve genetic engineering operations such as gene replacement, gene knock-out and knock-in between the genome and exogenous DNA. For example, it can be recombinase-mediated cassette exchange, for example, it can be CRISPR / Cas9-mediated gene targeted integration.
[0111] Fifth aspect of the present invention
[0112] The present invention provides a method for producing a target gene expression product, the method comprising the following steps: culturing the targeted integration cell described in the third aspect, and collecting the target gene expression product.
[0113] In some embodiments of the present invention, the targeted integrated cells according to this method are stable and high-yielding.
[0114] In some embodiments of the present invention, the nucleotide sequence of the integration site and / or the nucleotide sequence flanking the integration site can be identified experimentally: in some embodiments of the present invention, the nucleotide sequence of the integration site and / or the nucleotide sequence flanking the integration site can be identified by a whole genome screening method to isolate host cells; in some embodiments of the present invention, the nucleotide sequence of the integration site and / or the nucleotide sequence flanking the integration site can be identified by a whole genome screening method after a transposase-based cassette integration event; in some embodiments of the present invention, the nucleotide sequence of the integration site and / or the nucleotide sequence flanking the integration site can be identified by a brute force random integration screening; in some embodiments of the present invention, the nucleotide sequence of the integration site and / or the nucleotide sequence flanking the integration site can be determined by conventional sequencing methods (such as target locus amplification), followed by next-generation sequencing and whole genome sequencing; in some embodiments of the present invention, the location of the integration site on the chromosome can be determined by conventional cell biology methods (such as fluorescence in situ hybridization analysis). Specific embodiments
[0116] The embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are preferably referred to the guidance provided in the present invention, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.
[0117] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.
[0118] The consumables in the following specific embodiments involve: Neon Resuspension Buffer R (ThermoFisher), a resuspension buffer for cell electroporation instrument, electroporation solution E (ThermoFisher), recovery medium EX-CELL Advanced CHO Fed-batch Medium (Sigma-Aldrich), expansion medium EX-CELL Advanced CHO Fed-batch Medium plus 200 μg / ml hygromycin (ThermoFisher) and 1% GlutaMAX (ThermoFisher), shake flask medium EX-CELL Advanced CHO Fed-batch Medium plus 1% GlutaMAX, basal medium in the fed-batch medium uses 100% EX-CELL Advanced CHO Fed-batch Medium, and feed medium is 4% Cell Boost 7a / 7b (HyClone).
[0119] Example 1
[0120] The operation flow of this embodiment can be found in Figure 1 , mainly includes the following steps:
[0121] (1) The green fluorescent protein gene (EGFP) was used as a screening marker gene, and the Attp sequence was used as a homology arm to construct a RMCE ( Figure 2 ) recombinant plasmid, see Figure 3 ;
[0122] (2) Amplifying and linearizing the constructed plasmid and using it for transfection;
[0123] (3) Take 3×10E 6 Place CHO cells into a 50 mL centrifuge tube, centrifuge at 1000 rpm for 5 min at room temperature, and discard the supernatant.
[0124] (4) Wash the cells with 5 mL of Ex-Cell Advanced CHO Fed-batch medium, centrifuge at 1000 rpm for 5 min at room temperature, and discard the supernatant;
[0125] (5) Resuspend the cells with 100 μL of resuspension buffer for the cell electroporator;
[0126] (6) Take 15 μg of the linearized plasmid and add it to the resuspended cells in step (5), mix gently, and pipette 50 times to avoid generating bubbles;
[0127] (7) Turn on the cell electroporator, adjust the parameters, install the motor slot into the electroporator, and add 3 mL of electroporation solution E into the slot;
[0128] (8) sucking the cell plasmid suspension from step (6) into the tip of the electroporation gun, placing it into the electroporation tank, and performing electroporation;
[0129] (9) Immediately transfer the electroporated cells into a 6-well plate with 2 mL of recovery medium and place in a 37°C, 5% CO 2 Incubate overnight in an incubator;
[0130] (10) 48 hours after electroporation, pressure screening was performed. The cells were passaged every 2-3 days. The cell viability first decreased and then increased. When the cell viability was greater than 90%, the cells were considered to be a stable cell pool.
[0131] (11) Using flow cytometry to sort the cells in the stable cell pool to screen for highly fluorescent cells, and obtaining 1% of cells with the highest fluorescence;
[0132] (12) After enrichment, the cells are precisely selected by fluorescence sorting using a precise selection system to complete monoclonalization;
[0133] (13) Monoclonal fluorescent cells are expanded and cultured to form cell lines, and fluorescence detection is performed in the shake flask stage. The high-fluorescence cell line is retained and recorded as GBB-01 cells;
[0134] (14) The high fluorescence cell line was subjected to a 90-day cell culture stability study to confirm that cells with small fluorescence value changes and stable cell line growth were stable high fluorescence cells. Figure 4 It shows that GBB-01 cells have stable growth after 90 days of passage, and Table 1 shows that the fluorescence expression of GBB-01 cells is stable;
[0135] Table 1
[0136] Mean fluorescence value Fluorescent cell percentage (%) P3 (Day 10) 25.5 100 P26 (Day 91) 22.3 100
[0137] (15) Referring to step (1), the target gene (Fc fusion protein) fragment was cloned into the plasmid to construct a plasmid containing RMCE ( Figure 5 ) recombinant plasmid, see Figure 6 ;
[0138] The target gene fragment has the sequence shown in SEQ ID No.2, SEQ ID No.2:
[0139] cacggcgagggcaccttcaccagcgatgtctcctcttacctggaagagcaggccgctaaagagttcatcgcctggctggtgaagggaggaggcggcggcgg aggctctggcggaggcggctccggcggcggtggctccgctgagtccaaatacggccctccatgtcctccttgccctgctcctgaggctgctggcggaccct ccgtgttcctgttccctcccaagcccaaggacaccctgatgatcagccggacccctgaagtgacctgtgtggtcgtggacgtgtctcaagaggaccctgag gtgcagtttaactggtacgtggatggcgtggaagtacataacgccaagaccaagcctcggggaggaacagttcaactccacctacagagtggtgtctgtgctg acagtgctccaccaggactggctgaacggcaaagagtacaagtgcaaggtctccaacaagggcctgccttcctccatcgagaagaccatctctaaggccaa gggccagcctagagagcctcaagtgtacaccctgcctccctctcaggaagagatgaccaagaatcaggtgagcctgacctgcctggtcaagggcttctacc cttctgatatcgccgtggaatgggagtctaatggccagcccgagaacaactacaaaaccacaccacctgtgctggactccgacggctccttcttcctgtac tccagactgaccgtggacaagtctagatggcaggagggcaacgtgttctcctgctccgtgatgcacgaggccctgcacaaccactataacacagaagtccttg agcctgtctctgggctga
[0140] (16) Select the stable high fluorescence cell GBB-01 in step (14) for transfection and integration verification, amplify and linearize the recombinant plasmid in the above step (15), and co-transfect it with Bxb-1 integrase into the stable high fluorescence cell GBB-01, and the transfection steps are as described above;
[0141] (17) Two days after transfection, the cell pool was subjected to pressure screening, and a stable cell pool was formed in about 2 weeks;
[0142] (18) Counting the proportion of non-fluorescent cells in the cell pool, and after the cell viability recovers to more than 90%, performing limiting dilution plating to monoclonize the cell pool;
[0143] (19) The non-fluorescent cells in the monoclonal cells were further amplified (using amplification medium), expanded to the shake flask stage (using shake flask medium), and the expression level was evaluated by fed-batch culture (using fed-batch culture medium). The expression level of the single-copy cell line of the fixed-site integrated product (referred to as product clone-1 or GBB-01-H8) was compared with the three-copy cell line of random integration cultured under the same conditions. The results are shown in Figure 7 ;
[0144] In order to investigate the stability of the targeted integration cell product Clone-1, the product Clone-1 was continuously cultured for about 90 days for stability assessment. The results of 7-day batch culture (cultivation with basal medium only) showed that the product Clone-1 cells had no significant difference in expression level ( Figure 8 ) and specific yield ( Fig. 9 ) all showed stability and high yield;
[0145] The quality attributes of some targeted integration cells were studied and compared with the cell line expression products obtained by the random integration method [1] in the following aspects:
[0146] The results showed that the quality attributes were similar and there were no significant differences. Fig.10 Sugar profile comparison results and Fig.11 Charge heterogeneity comparison results;
[0147] The second-generation whole genome sequencing was performed on the cell line GBB-01-H8, which highly expressed both fluorescence and target genes, and the annotation information of the integration site on CHO was obtained as follows: NC_048596:34375010 is located in the intergenic region.
[0148] The sequence fragment of NC_048596 after integration of the target gene is shown in SEQ ID No. 3, SEQ ID No. 3:
[0149]
[0150] The above-mentioned breakpoint upstream primer F (SEQ ID No. 4): tgcagccacactaagatgg and the product gene downstream primer R (SEQ ID No. 5): ccagagacaggctcaaggac on the product plasmid were used to amplify the product cell line genome to obtain a fragment that meets the theoretical size (2876 bp), such as Fig.12 (corresponding band of lane GBB-01-H8) is shown.
[0151] The amplified bands were recovered by gel excision, purified, and multiple pairs of primers were designed for DNA sequencing. The sequence of the sequencing results after splicing is shown below, which is consistent with the theoretical sequence (sequence SEQ ID No. 3), thus confirming that the target gene was correctly integrated into the target site.
[0152] References:
[0153] [1]Takeshi Omasa et al,.Cell engineering and cultivation of chinesehamster ovary(CHO)cells.Curr Pharm Biotechnol.2010Apr;11(3):233-40.
[0154] Example 2
[0155] (1) Construction of Cas9 editing plasmid:
[0156] Design an sgRNA (SEQ ID No.6: gatagtcacccacaccagaggttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgc; GC=55%, no secondary) that can target the 1678-1744 base interval of the nucleic acid fragment shown in SEQ ID No.1, and merge and anneal the double strands. The reaction system is 5 μL of each forward and reverse oligo, 5 μL of 10×NEB buffer 2, and water is added to 50 μL. The system is incubated at 95°C (must be measured with a thermometer) for 5 minutes, and then naturally cooled to 25°C. The resulting product plasmid is connected to the pDonor CRISPR / Cas9 vector cut with PvuI. The ligation product was transformed into DH5α competent medium and coated on ampicillin-resistant LB solid plate. The next day, a single clone was picked and the plasmid was extracted. Finally, the correct Cas9 encoding plasmid was verified by first-generation sequencing.
[0157] (2) Construction of donor plasmid:
[0158] The donor plasmid is composed of a 5' homology arm, an anti-PD1 monoclonal antibody encoding gene, a hygromycin encoding gene and a 3' homology arm connected in series on a pUC19 plasmid.
[0159] (3) Electroporation transfection of Cas9 encoding plasmid and anti-PD1 donor plasmid:
[0160] Use suspension-type Chinese hamster ovarian cancer cells, namely CHOK1 cell line. The cell density was adjusted to 5×10 5 The next day, electroporation was used for transfection, with a voltage of 1575 V, a pulse duration of 10 ms, and 3 pulses. A 6-well plate was used for cell culture, with 3×10 6 cells, the culture medium volume is 2 mL, and the required plasmid is 15 μg. After transfection, place in a 37°C, 5% CO 2 Among them, adding Cas9 encoding plasmid and anti-PD1 donor plasmid for co-transfection can obtain a fixed-site integrated cell pool, and adding only anti-PD1 donor plasmid for transfection can obtain a random integrated cell pool expressing anti-PD1.
[0161] (4) Pressure screening and enrichment of site-specific integrated cell pools.
[0162] (5) Preliminary identification of the site-specific integrated cell pool by 5' / 3' junction PCR, sequencing of the amplified target fragment, and collection of the supernatant after confirmation of the site-specific integrated cell pool.
[0163] (6) Western blot was used to detect the expression of anti-PD1 antibodies in the site-specific integrated cell pool, confirming that the site-specific integrated cell pool was obtained. After 3 weeks of drug addition screening, the expression of anti-PD1 antibodies in the random integrated cell pool was basically undetectable by Western blot, while the expression of anti-PD1 antibodies in the site-specific integrated cell pool was higher.
[0164] (7) Obtaining monoclonal cell lines by limiting dilution method: Obtain monoclonal cell lines by limiting dilution method using the previously targeted integration cell pool. The cell pool is plated on a 96-well plate with a cell density of 0.8 cells / well. The plate is checked on the same day to confirm the monoclonality. When the cells have grown for about 5 weeks, aspirate 1×10 6 The genomic DNA was extracted and 5' / 3' junction PCR was performed again, the method was the same as step (5). The positive cell lines obtained by junction PCR were further tested by Western blot to determine whether the anti-PD1 antibody was correctly expressed.
[0165] (8) Evaluation of the expression of anti-PD1 antibodies in targeted integration cell lines: The expression of anti-PD1 antibodies in targeted integration cell lines was approximately 2.3 times that in random integration cell lines.
[0166] Example 3
[0167] Table 2
[0168] Integration site Anti-PD1 antibody expression level of targeted integrated cell lines (mg / L) NC_048596:34373499 621 NC_048596:34374860 726 NC_048596:34375011 705 NC_048596:34375099 689 NC_048596:34376119 536 Single copy random integration cell line 285mg / L
[0169] Targeted integrated cells were constructed according to the steps of Example 1, and the single-copy randomly integrated cell line was used as a control. The expression levels of 6-well plate batch culture in the basal culture medium are shown in Table 2, wherein the expression level of anti-PD1 antibody of the single-copy randomly integrated cell line in 6-well plate batch culture was 285 mg / L, while the expression level of the targeted integrated cell line was more than twice that level.
[0170] The technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. To make the description concise, not all possible combinations of the technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0171] The above-described embodiments only express several implementation methods of the present invention, which is convenient for understanding the technical solutions of the present invention in detail, but cannot be understood as limiting the scope of protection of the invention patent. It should be pointed out that, for those of ordinary skill in the art, without departing from the concept of the present invention, several variations and improvements can be made, which all belong to the protection scope of the present invention. In addition, it should be understood that after reading the above-mentioned teaching content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and the equivalent forms obtained also fall within the protection scope of the present invention. It should also be understood that the technical solutions obtained by those skilled in the art on the basis of the technical solutions provided by the present invention through logical analysis, reasoning or limited experiments are all within the protection scope of the claims attached to the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the contents of the attached claims, and the description and drawings can be used to explain the contents of the claims. Sequence Listing <110> Shenzhen Taili Biotechnology Co., Ltd. <120> Targeted integration cell and preparation method thereof, and method for producing target gene expression product <160> 6 <170> SIPOSequenceListing 1.0 <210> 1 <211> 3150 <212> DNA <213> Chinese Hamster (Cricetulus barabensis) <400> 1 gattggcccc agagaagcac agagagccaa gggaggcttc ccgattataa aaaaaaatgc 60 tgccttccaa ggctagtcct gctcacttct tttgggtctc agggttaagc tctgccattc 120 ctgttagtca caaacaaatt aagtcagtaa cagcaacaca tcttgcttga gtttgaagac 180 aagccaatga cacacatagt ttccagaaga ccctctccca ggactcccta tagcaggagc 240 gtgtgggaga gagccaatga cttatcagtc acctactaca ccaccccttt ttacagtttc 300 tgcagccaac agctgcaccc tccttaacag tctgcatttc tctcttttcc ggtctgttgt 360 gttctttcct agttggagat gctacctgtt tttgtttgaa ttacttactg gaatagacaa 420 gtaaaggtct ctttgtcctt agactcatca ccctctctgc tacagcatgc ttaaaaaaaa 480 aaaaagtttg atcatgttat ttattgtta aaaatatttg gctcttctcc aaagcattga 540 ggctgaaatt gaaagtcttt ctgtagagtg gcaaaatgaa aatgtcaaca gactttttat 600 aagtcttttt ctagaagggt gtagaaggt ccagaccaca ggtaactgct tctttattat 660 cttcttgcgg caatagaaga gagtgggcct tctggaacac aaactatgtg gctagacaga 720 aagatcaggt ccctaaggcc aaagcttggc ctggaagctt ccatctgggt catgttgtaa 780 ggtgaactga agttttatcc tctaaaattc atatgtccaa attgtgatgc ctggtgtgat 840 ggaattagga ggagggactc tttaaggaat agtattagat catggtgtag ggcccttggg 900 agtaaaggct tttattaaag gggtcacagg tagccttcta gccttcctgc atgtgagctt 960 atgctgagaa gtgggaaggg tgtcctcctt catatagaca tctgttttg aaccttcagt 1020 ttcatggaac tgagagaat agtttgtggt tcataggca gatagtgtat ttgttcaac 1080 agccaggcct gagcaagct cctataaaa tattgaattt ccagttaacc ttcagttttca 1140 ggaaacaatg actaacttt gagattgtat tttagtaac atttatgggt ctgaagtcca 1200 acttttacta ggtatcctgt atcttttat ctgccaaata tgataacctc ataccagtat 1260 ggggtggaag gtgaggctga ggacagtgac caggaggag aaatctgagc tccagcaaaa 1320 ggactgccag ttaaatgtga cagataacaa aggtccactt agctccactt agaaaaacct 1380 ccagaataa aggaatga cacaatggc aaaaataatgg catgaagaa atgggaactaa 1440 tacctgatag taggtacag atttcaaac atttttggatc atagaaaata acatataat 1500 gggaactaat tagcatagtg ctggtagggg tgttgacaag aagagacacc tattaagcag 1560 acttagaaa ggcagctggg ggtgacaag taacaaata atgcagccac actagatgg 1620 caaatgccac tcaactatac atttcaata gttaaggtgg tgaattaagc agtaaatatt 1680 ttaccacaac tgatagtgta agaaaacaaa ctgaagtaga tagtcaccca caccagagac 1740 aaagacagaa ggctaaaacc tcctggggaa ggaagaggtc tcagatcaag aattagacac 1800 agctctgact caagccacgg ggaacagttg ggaaatccct tcacagttct gtgggaaaaa 1860 tacttccaga caagaacttt atctcatggc aagctatcaa ggatatcacc tgcaagtgta 1920 gattgaagac atgaaggcag gattagtgtc ccaggaggat atgccaaggc aatagaaggc 1980 caaacaaagc tggctacctc agcttggcct tgctatcact gcttcaaccc ttgagtccct 2040 agccccagat acattacact tggacactta aggtctcaag tgttacaagt acagcggtcc 2100 ttgctctcac aggtaagcac tagggatacc agaaatgcta acatgtggag ttgtctcttt 2160 aatggaagag atttataacc tgttttctcc cagaagcctg agaatggagg tggctaatag 2220 ccttaagtga tccttgtttt atctgtatga ccagggactc ccccaagctc ccacaactag 2280 gatttgaggt ggccaatagt ctaggtgact tctgtgctat cctgtatgac caagaccata 2340 ccagattctc cccctaggcc cttaagataa cacaggtagc ccatctttag aatccatcct 2400 tatggaagaa gcaccatgta ctttgagaag agttttgatg tgattatgct tccttgtata 2460 caggggattg tgttatagta gaaaactttt ctccaaattg tactgtacct caatatgcct 2520 aaaataaaca gcctggcatc agactctaga agtttgaacc aacattagct actgagatgt 2580 gttgaaccag atttccttct tgccttcatg gattgttact ctgcttttca tagatgtccg 2640 cattcaagaa tccctgcctc ataacatcac tgctcaccag ctaatagaat tggctatcat 2700 accttctacc cagtgaatag accaaggttc attachttt ataccatccc atttcatccg 2760 tcaacttatc cctttttttt ttttctgatg tctgatgggg aatccaagtc tcaggtagga 2820 atctgttggg shit taaaggcctt shit taatgttact gagaattgta 2880 gctatagaaa gggaaaggtc tccacattga gactggatgt gtgtgtgtgt gtgtgtgtgt 2940 gtgtgttggg agggaggggg agttcatttt taatttctcc caagaagcag aatgcattca 3000 ttcattcagt tgaagcattt tgtgtactat gtttacactc tactagaatt atgtggacta 3060 ttagataatg gcttctgcta tctaattcca ttaactttac ttttttaagg aaaaatttgt 3120 gtaataaatc aatattaaaa cagctttatt 3150 <210> 2 <211> 828 <212> DNA <213> Artificial Sequence <400> 2 cacggcgagg gcaccttcac cagcgatgtc tcctcttacc tggaagagca ggccgctaaa 60 gagttcatcg cctggctggt gaagggagga ggcggcggcg gaggctctgg cggaggcggc 120 tccggcggcg gtggctccgc tgagtccaaa tacggccctc catgtcctcc ttgccctgct 180 cctgaggctg ctggcggacc ctccgtgttc ctgttccctc ccaagcccaa ggacaccctg 240 atgatcagcc ggacccctga agtgacctgt gtggtcgtgg acgtgtctca agaggaccct 300 gaggtgcagt ttaactggta cgtggatggc gtggaagtac ataacgccaa gaccaagcct 360 cgggaggaac agttcaactc cacctacaga gtggtgtctg tgctgacagt gctccaccag 420 gactggctga acggcaaaga gtacaagtgc aaggtctcca acaagggcct gccttcctcc 480 atcgagaaga ccatctctaa ggccaagggc cagcctagag agcctcaagt gtacaccctg 540 cctccctctc aggaagagat gaccaagaat caggtgagcc tgacctgcct ggtcaagggc 600 ttctaccctt ctgatatcgc cgtggaatgg gagtctaatg gccagcccga gaacaactac 660 aaaaccacac cacctgtgct ggactccgac ggctccttct tcctgtactc cagactgacc 720 gtggacaagt ctagatggca ggagggcaac gtgttctcct gctccgtgat gcacgaggcc 780 ctgcacaacc actatacaca gaagtccttg agcctgtctc tgggctga 828 <210> 3 <211> 2876 <212> DNA <213> Artificial Sequence <400> 3 tgcagccaca ctaagatggc aaatgccact caactataca tttcaaatag ttaaggtggt 60 gaattaagca gtaaatattt taccacaact gatagtgtaa gaaaacaaac cgtcgtgtag 120 ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat accgcgagac 180 ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc 240 agaagtggtc ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct 300 agagtaagta gttcgccagt taatagtttg cgcaacgttg ttgccattgc tacaggcatc 360 gtggtgtcac gctcgtcgtt tggtatggct tcattcagct ccggttccca acgatcaagg 420 cgagttacat gatcccccat gttgtgcaaa aaagcggtta gctccttcgg tcctccgatc 480 gttgtcagaa gtaagttggc cgcagtgtta tcactcatgg ttatggcagc actgcataat 540 tctcttactg tcatgccatc cgtaagatgc tttctgtga ctggtgagta ctcaaccaag 600 tcattctgag aatagtgtat gcggcgaccg agttgctctt gcccggcgtc aatacgggat 660 aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg 720 cgaaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca 780 cccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga 840 aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc 900 ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata 960 tttgaatgta tttagaaaaa taacaaata ggggttccgc gcacatttcc ccgaaaagtg 1020 ccacctgacg tcgacggatc gggagatctc ccgatcccct atggtcgact ctcagtacaa 1080 tctgctctga tgccgcatag ttaagccagt atctgctccc tgcttgtgtg ttggaggtcg 1140 ctgagtagtg cgcgagcaaa atttaagcta caacaaggca aggcttgacc gacaattgca 1200 tgaagaatct gcttagggtt aggcgttttg cgctgcttcg cgatgtaggt ttgtctggtc 1260 aaccaccgcg gtctccgtcg tcaggatcat gacattgatt attgactagt tattaatagt 1320 aatcaattac ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta 1380 cggtaaatgg cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga 1440 cgtatgttcc catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt 1500 tacggtaaac tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta 1560 ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg 1620 actttcctac ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt 1680 tttggcagta catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc 1740 accccattga cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat 1800 gtcgtaacaa ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct 1860 atataagcag agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt 1920 ttgacctcca tagagacac cgggaccgat ccagcctccg ggatccagat cttctagaaa 1980 gcttggtacc gatatcatgg aactgggcct gcggtgggtg tttctggtgg ccatcctgga 2040 aggcgtgcag tgccacggcg agggcacctt caccagcgat gtctcctctt acctggaaga 2100 gcaggccgct aaagagttca tcgcctggct ggtgaaggga ggaggcggcg gcggaggctc 2160 tggcggaggc ggctccggcg gcggtggctc cgctgagtcc aaatacggcc ctccatgtcc 2220 tccttgccct gctcctgagg ctgctggcgg accctccgtg ttcctgttcc ctcccaagcc 2280 caaggacacc ctgatgatca gccggacccc tgaagtgacc tgtgtggtcg tggacgtgtc 2340 tcaagaggac cctgaggtgc agtttaactg gtacgtggat ggcgtggaag tacataacgc 2400 caagaccaag cctcgggagg aacagttcaa ctccacctac agagtggtgt ctgtgctgac 2460 agtgctccac caggactggc tgaacggcaa agagtacaag tgcaaggtct ccaacaaggg 2520 cctgccttcc tccatcgaga agaccatctc taaggccaag ggccagccta gagagcctca 2580 agtgtacacc ctgcctccct ctcaggaaga gatgaccaag aatcaggtga gcctgacctg 2640 cctggtcaag ggcttctacc cttctgatat cgccgtggaa tgggagtcta atggccagcc 2700 cgagaacaac tacaaaacca caccacctgt gctggactcc gacggctcct tcttcctgta 2760 ctccagactg accgtggaca agtctagatg gcaggagggc aacgtgttct cctgctccgt 2820 gatgcacgag gccctgcaca accactatac acagaagtcc ttgagcctgt ctctgg 2876 <210> 4 <211> 19 <212> DNA <213> Artificial Sequence <400> 4 tgcagccaca ctaagatgg 19 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <400> 5 ccagagacag gctcaaggac 20 <210> 6 <211> 96 <212> DNA <213> Artificial Sequence <400> 6 gatagtcacc cacaccagag gttttagagc tagaaatagc aagttaaaat aaggctagtc 60 cgttatcaac ttgaaaaagt ggcaccgagt cggtgc 96
Claims
1. A recombinant vector, characterized in that: The vector comprises: a. a 5' homology arm homologous to the sequence fragment present in the nucleic acid fragment shown in SEQ ID No.1, b. Target gene, c. a 3' homology arm homologous to the sequence fragment present in the nucleic acid fragment shown in SEQ ID No.1; The recombinant vector targets Chinese hamster ovary CHO cells; The target gene is integrated at any site within the 200-2820 bp interval of the nucleic acid shown in SEQ ID No.
1.
2. The recombinant vector according to claim 1, characterized in that The target gene is integrated at any site within the 324th to 2688th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
3. The recombinant vector according to claim 2, characterized in that The target gene is integrated at any site within the 480th to 2460th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
4. The recombinant vector according to claim 3, characterized in that The target gene is integrated at any site within the 700th to 2200th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
5. The recombinant vector according to claim 4, characterized in that The target gene is integrated at any site within the 976th to 1900th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
6. The recombinant vector according to claim 5, characterized in that The target gene is integrated at any site within the 1260th to 1879th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
7. The recombinant vector according to claim 6, characterized in that The target gene is integrated at any site within the 1561st to 1800th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
8. The recombinant vector according to claim 7, characterized in that The target gene is integrated at any site within the 1678th to 1744th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
9. The recombinant vector according to claim 8, characterized in that The target gene is integrated at any site within the 1701-1720 base interval of the nucleic acid fragment shown in SEQ ID No.
1.
10. The recombinant vector according to any one of claims 1 to 9, characterized in that The target gene encodes one or more of antibodies, recombinant proteins, polypeptides, enzymes, hormones, growth factors and receptors.
11. The recombinant vector according to any one of claims 1 to 9, characterized in that The recombinant expression vector is a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a herpes virus vector, a poxvirus vector, a baculovirus vector, a papillomavirus vector, a papillomas virus vector, an integrating phage vector, a non-viral vector, a transposon and / or a transposase, an integrase substrate or a plasmid.
12. Targeted integration cell, characterized in that The targeted integration cell comprises the nucleic acid fragment shown in SEQ ID No. 1; an exogenous nucleic acid fragment is integrated into the nucleic acid fragment; The exogenous nucleic acid fragment is integrated into any site within the 200-2820 bp interval of the nucleic acid fragment shown in SEQ ID No. 1; The targeted integration cells are Chinese Hamster Ovary (CHO) cells.
13. The targeted integrated cell according to claim 12, characterized in that: The exogenous nucleic acid fragment is integrated at any site within the 324th to 2688th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
14. The targeted integrated cell according to claim 13, characterized in that: The exogenous nucleic acid fragment is integrated at any site within the 480th to 2460th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
15. The targeted integrated cell according to claim 14, characterized in that: The exogenous nucleic acid fragment is integrated at any site within the 700th to 2200th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
16. The targeted integrated cell according to claim 15, characterized in that: The exogenous nucleic acid fragment is integrated at any site within the 976th to 1900th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
17. The targeted integrated cell according to claim 16, characterized in that: The exogenous nucleic acid fragment is integrated at any site within the 1260th to 1879th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
18. The targeted integrated cell according to claim 17, characterized in that: The exogenous nucleic acid fragment is integrated at any site within the 1561-1800 base interval of the nucleic acid fragment shown in SEQ ID No.
1.
19. The targeted integrated cell according to claim 18, characterized in that: The exogenous nucleic acid fragment is integrated at any site within the 1678th to 1744th base interval of the nucleic acid fragment shown in SEQ ID No.
1.
20. The targeted integrated cell according to claim 19, characterized in that The exogenous nucleic acid fragment is integrated at any site within the 1701-1720 base interval of the nucleic acid fragment shown in SEQ ID No.
1.
21. The targeted integrated cell according to any one of claims 12 to 20, characterized in that: The exogenous nucleic acid fragment comprises: a first recombination recognition sequence and a second recombination recognition sequence recognized by a recombinase, a selection marker gene and a target gene located between the first recombination recognition sequence and the second recombination recognition sequence, and a promoter regulating the expression of the selection marker gene and the target gene.
22. The targeted integrated cell according to claim 21, characterized in that: The recombinase is Bxb1 integrase, ΦC31 integrase, Cre recombinase or FLP recombinase; or / and, The first recombination recognition sequence and the second recombination recognition sequence are independently selected from one or more of the following sequences: LoxP sequence, LoxPL3 sequence, LoxP 2L sequence, LoxFas sequence, Lox511 sequence, Lox2272 sequence, Lox2372 sequence, Lox5171 sequence, Loxm2 sequence, Lox71 sequence, Lox66 sequence, FRT sequence, Bxb1 attP sequence, Bxb1 attB sequence, attP sequence and attB sequence.
23. The targeted integrated cell according to claim 21, characterized in that: The selection marker gene is selected from one or more of a neomycin resistance gene, a thymidine kinase gene, a hygromycin phosphotransferase gene, a dihydrofolate reductase gene, a glutamine synthetase gene, an asparagine synthetase gene, a tryptophan synthetase gene, a histidinol dehydrogenase gene, an aminoglycoside phosphotransferase gene and a fluorescent protein gene.
24. The targeted integrated cell according to claim 21, characterized in that: The promoter is CMV promoter, SV40 promoter, RSV promoter, β-globin promoter, UBC promoter, EF1a promoter, ubiquitin promoter, β-actin promoter, PGK1 promoter, Rosa26 promoter, HSP70 promoter, GAPDH promoter, Eif4A1 promoter, Egr1 promoter, FerH promoter, SM22α promoter or Endothelin-1 promoter.
25. The targeted integrated cell according to claim 21, characterized in that: The target gene encodes one or more of antibodies, recombinant proteins, polypeptides, enzymes, hormones, growth factors and receptors.
26. The method for preparing targeted integrated cells according to any one of claims 12 to 25, characterized in that: The preparation method comprises the following steps: Chinese hamster ovary CHO cells are provided, and the exogenous nucleic acid fragment is integrated into the nucleic acid fragment shown in SEQ ID No. 1 to prepare targeted integrated cells.
27. A method for producing a target gene expression product, characterized in that: The method comprises the following steps: culturing the targeted integration cell according to any one of claims 12 to 25, and collecting the expression product of the target gene in the exogenous nucleic acid fragment.
